Abstract
KEY POINTS:
- Biomarker-related clinical trials for immune checkpoint inhibitor (ICI) therapy in melanoma have mostly described prognostic rather than predictive biomarkers.
- Quantifying immune checkpoint regulator receptor-ligand activity within the tumor microenvironment (TME) may provide a more sensitive readout of biomarker activity during ICI therapy.
- Biomarker functional activity determined by spatial and quantitative imaging platforms has the potential to significantly improve design/quality of predictive biomarker clinical trials for ICI therapy in melanoma.
- Biomarker-related clinical trials for immune checkpoint inhibitor (ICI) therapy in melanoma have mostly described prognostic rather than predictive biomarkers.
- Quantifying immune checkpoint regulator receptor-ligand activity within the tumor microenvironment (TME) may provide a more sensitive readout of biomarker activity during ICI therapy.
- Biomarker functional activity determined by spatial and quantitative imaging platforms has the potential to significantly improve design/quality of predictive biomarker clinical trials for ICI therapy in melanoma.
| Original language | English |
|---|---|
| Pages (from-to) | 437-451 |
| Number of pages | 15 |
| Journal | Surgical Oncology Clinics of North America |
| Volume | 34 |
| Issue number | 3 |
| Early online date | 28 Feb 2025 |
| DOIs | |
| Publication status | Published - 1 Jul 2025 |
Keywords
- Biomarker
- Immune checkpoint
- Immunotherapy
- Melanoma
- Predictive
- Quantitative
- Spatial
ASJC Scopus subject areas
- Surgery
- Oncology